Transferrin-binding antibodies and uses thereof
Transferrin-binding proteins provide targeted drug delivery across biological barriers by specifically binding transferrin, enhancing efficiency and safety for both central nervous system targeting and oral administration of biologics.
Patent Information
- Application Number
- JP2024529794
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2021-12-02
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2041-12-02
AI Technical Summary
Current drug delivery technologies face challenges in efficiently crossing biological barriers such as the blood-brain barrier and intestinal epithelium, particularly for large molecule biologics, with existing methods often causing adverse effects and limited oral delivery options.
Utilization of transferrin-binding proteins that specifically bind transferrin without interfering with transferrin receptor interaction, enabling targeted drug delivery across cell membranes, including the blood-brain barrier and intestinal epithelium, through transcytosis.
Enhances drug delivery efficiency by maintaining normal physiological function, extending circulating half-life, and allowing oral delivery of biologics while minimizing adverse effects.
Smart Images

Figure 2024543867000002 
Figure 2024543867000003 
Figure 2024543867000004
Abstract
Description
[Background technology]
[0001] Transmembrane drug delivery systems can be applied to blood-brain barrier (BBB) crossing drug delivery, oral drug delivery, intracellular drug delivery, etc. Currently, among non-invasive blood-brain barrier drug delivery techniques such as receptor-mediated BBB crossing drug delivery, the transferrin receptor (TfR) is the most widely studied target protein. These TfR-targeting vehicles include antibody clones known as OX26 and 8D3 in formats as Fab, scFv, or dual variable domain immunoglobulins, a peptide known as GYR22, and an engineered Fc region of human IgG with TfR-binding properties. Most of such approaches are still in the preclinical stage, but some studies have shown promising results in clinical trials, despite some limitations.
[0002] The affinity and valency of TfR antibodies can alter the intracellular trafficking of TfR and multiple therapeutic entities delivered; high affinity bivalent TfR antibodies have been shown to divert antibody-TfR complexes to lysosomes, resulting in degradation and reduced levels of TfR. Thus, TfR antibodies used for transmembrane drug delivery need to be optimal with respect to affinity to TfR and / or monovalent to achieve higher efficiency of transcytosis into the brain. The efficiency of TfR-targeted delivery techniques may vary depending on the biological or biochemical characteristics of the entities to be delivered, and anti-TfR antibodies may also cause acute clinical signs and reduced circulating reticulocyte counts. The ubiquitous expression of TfR throughout the body suggests that TfR-targeted strategies likely result in enhanced uptake of TfR-targeted drugs into peripheral compartments such as the bone marrow, liver, and spleen.
[0003] With some exceptions, oral administration is currently only an option for small drug molecules that exhibit acceptable intestinal absorption. Biologics, as a rapidly expanding class of drugs, are currently administered primarily by injection. Considerable research efforts over several decades have explored technologies that would enable oral delivery of biologics, but progress has been relatively unimpressive. Drug delivery strategies in this field primarily utilize absorption or permeation enhancers such as SNAC or focus on relatively small mass biologics such as glucagon-like peptide 1 (GLP-1) analogs. However, safety concerns, including those associated with many of the surfactants used in formulation, have prevented translation of these approaches to the clinic. A key challenge in the field of oral delivery of macromolecular biologics relates to the difficulty of overcoming the formidable intestinal epithelial barrier, rather than additional barriers such as gastric acid and mucosal enzymes that can be addressed via relatively well-established technologies. A key requirement of technologies that enable therapeutically relevant oral delivery of biologics is safety. It is desirable to design delivery systems that selectively permeate the intestinal mucosa rather than nonselectively disrupting and increasing the permeability of the intestinal epithelium (i.e., an effect that classical permeation enhancers would exhibit). Summary of the Invention
[0004] The present disclosure provides methods for translocating molecules across cell membranes by using transferrin binding proteins that can specifically bind to transferrin and do not interfere with the interaction between transferrin and the transferrin receptor.
[0005] In one aspect, the disclosure provides a method for translocating molecules across a cell membrane by using transferrin binding proteins.
[0006] In some embodiments, the transferrin binding protein comprises a transferrin binding antibody or fragment thereof.
[0007] In some embodiments, the methods are used for drug delivery across the cell membrane of polarized and / or non-polarized cells.
[0008] In some embodiments, the polarized cells and / or the non-polarized cells express a transferrin receptor on their cell membrane.
[0009] In some embodiments, drug delivery across the plasma membrane of polarized cells includes intracellular delivery of the drug and / or recycling of endocytosed drug back into the circulation.
[0010] In some embodiments, drug delivery across the cell membrane of non-polarized cells includes crossing the blood-brain barrier (BBB) for systemically administered drugs targeted to the central nervous system (CNS), crossing the intestinal epithelium for orally administered drugs, and / or permeation of drugs through multiple layers of cells in solid tissues.
[0011] In some embodiments, the drug comprises a therapeutic or diagnostic agent.
[0012] In some embodiments, the drug comprises a small molecule compound, a synthetic peptide, a recombinant protein, an antibody or antibody fragment, an enzyme, a portion of a nucleotide acid sequence, a liposome, a lipid nanoparticle, a drug vehicle, a synthetic nucleotide sequence, a modified virus, and / or a gene therapy vector.
[0013] In some embodiments, the drug is associated with the transferrin binding protein through chemical conjugation or genetic fusion.
[0014] In another aspect, the disclosure provides transferrin binding proteins capable of extending the circulatory half-life of its associated entities.
[0015] In some embodiments, the transferrin binding protein enables a drug that includes the transferrin binding protein to cross the blood-brain barrier (BBB).
[0016] In some embodiments, transferrin binding proteins are used for oral delivery of drugs.
[0017] In some embodiments, the transferrin binding protein enables intracellular delivery of its associated entity to a transferrin receptor expressing cell.
[0018] In some embodiments, the transferrin binding protein is capable of specifically binding to transferrin and does not interfere with the interaction between transferrin and transferrin receptor 1.
[0019] In some embodiments, the transferrin is human transferrin.
[0020] In some embodiments, the transferrin binding protein has a higher affinity for iron-containing holo-transferrin than for iron-free apo-transferrin.
[0021] In some embodiments, the transferrin binding protein comprises a monoclonal antibody, a single chain antibody fragment, a single domain antibody fragment, an engineered protein, or a peptide.
[0022] In some embodiments, the antibody or antibody fragment comprises an animal-derived sequence, a humanized sequence, a fully human sequence, a chimeric sequence, or a synthetic sequence.
[0023] In some embodiments the antibody or antibody fragment is a single domain antibody fragment VHH.
[0024] In some embodiments, the transferrin binding protein comprises a CDR3, wherein the CDR3 comprises an amino acid sequence set forth in any one of SEQ ID NOs:45-69.
[0025] In some embodiments, the transferrin binding protein comprises CDR1, CDR2 and CDR3, and CDR3 comprises the amino acid sequence set forth in any one of SEQ ID NOs:45-69.
[0026] In some embodiments, the transferrin binding protein comprises a heavy chain variable region VH, and the heavy chain variable region VH comprises an amino acid sequence shown in any one of SEQ ID NOs: 70-104.
[0027] In another aspect, the disclosure provides a polypeptide comprising a transferrin binding protein and a therapeutic entity.
[0028] In some embodiments, the therapeutic entity comprises an engineered cytotoxic Pseudomonas exotoxin A (PE38).
[0029] In some embodiments, the therapeutic entity is glucagon-like peptide-1 (GLP-1) or a variant thereof.
[0030] In some embodiments, the therapeutic entity and the antigen binding protein are linked directly or indirectly.
[0031] In some embodiments, the therapeutic entity and the transferrin binding protein are linked through a linker.
[0032] In another aspect, the disclosure provides one or more isolated nucleic acid molecules encoding a transferrin binding protein, or a polypeptide set forth in any one of SEQ ID NOs:70-106.
[0033] In another aspect, the present disclosure provides a vector comprising a nucleic acid molecule encoding a polypeptide set forth in any one of SEQ ID NOs:70-106.
[0034] In another aspect, the present disclosure provides a cell comprising a nucleic acid molecule or vector expressing a polypeptide set forth in any one of SEQ ID NOs:70-106.
[0035] In another aspect, the disclosure provides a method of preparing a transferrin binding protein or polypeptide, the method comprising culturing cells under conditions that allow the transferrin binding protein or polypeptide to be expressed.
[0036] In another aspect, the disclosure provides a pharmaceutical composition comprising a transferrin binding protein or polypeptide.
[0037] In another aspect, the disclosure provides a method of increasing the circulatory half-life of a therapeutic entity, wherein the therapeutic entity is directly or indirectly linked to a transferrin binding protein.
[0038] In another aspect, the disclosure provides a method of delivering a therapeutic or diagnostic agent to a cell or organ expressing a transferrin receptor, the method comprising using a transferrin-binding entity.
[0039] In another aspect, the disclosure provides a method of targeted drug delivery across the blood-brain barrier, intestinal epithelium, and / or cell membranes expressing transferrin receptors, comprising using a transferrin binding entity.
[0040] In another aspect, the disclosure provides a method for oral delivery of a therapeutic or diagnostic entity, wherein the therapeutic or diagnostic entity is directly or indirectly linked to an antigen binding protein.
[0041] In another aspect, the disclosure provides a method for intracellular delivery of a therapeutic entity, wherein the therapeutic entity is directly or indirectly linked to an antigen binding protein.
[0042] The present disclosure provides a technical solution that utilizes Tf instead of TfR for targeting based drug delivery systems, which offers multiple potential advantages in terms of specificity, safety, efficacy and circulation half-life.
[0043] Further aspects and advantages of the present disclosure will become readily apparent to those skilled in the art from the following detailed description, in which only illustrative embodiments of the present disclosure are shown and described. As will be understood, the present disclosure is capable of other and different embodiments, and its several details are capable of modification in various obvious respects, all without departing from the present disclosure. Accordingly, the drawings and description are to be regarded as illustrative in nature, and not as restrictive.
[0044] Incorporation by Reference All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
[0045] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings (also referred to herein as "figure" and "FIG.") [Brief description of the drawings]
[0046] [Figure 1] FIG. 1 shows a representative SDS-PAGE of transferrin binding protein-OVA-his protein expressed in HEK293 cells. [Figure 2A] FIG. 1 shows representative transferrin-mediated binding of selected transferrin-binding protein OVA-His protein to human transferrin at pH 7.4. [Figure 2B]FIG. 1 shows representative transferrin-mediated binding of selected transferrin-binding protein OVA-His protein to human transferrin at pH 6.0. [Figure 3A] FIG. 1 shows transferrin-mediated binding of selected transferrin-binding protein OVA-His proteins to transferrin receptor expressing cells. [Figure 3B] FIG. 1 shows transferrin-mediated binding of selected transferrin-binding protein OVA-His proteins to transferrin receptor expressing cells. [Figure 3C] FIG. 1 shows transferrin-mediated binding of selected transferrin-binding protein OVA-His proteins to transferrin receptor expressing cells. [Figure 4] FIG. 1 shows epitope binning of representative transferrin binding proteins of the present disclosure. [Figure 5A] FIG. 1 shows representative ELISA data demonstrating binding of humanized transferrin binding protein variants to native human transferrin at pH 7.4. [Figure 5B] FIG. 1 shows representative ELISA data demonstrating binding of humanized transferrin binding protein variants to native human transferrin at pH 6.0. [Figure 5C] FIG. 1 shows representative ELISA data demonstrating binding of humanized transferrin binding protein variants to native human transferrin at pH 7.4. [Figure 5D] FIG. 1 shows representative ELISA data demonstrating binding of humanized transferrin binding protein variants to native human transferrin at pH 6.0. [Figure 6A] FIG. 1 shows the circulating half-life of OVA fused to transferrin-binding proteins of clones of the present disclosure bearing different epitopes. [Figure 6B] FIG. 1 shows the circulating half-life of GLP-1-VHH in mice. [Figure 6C]FIG. 1 shows that VHH-enabled circulating half-life extension is affinity dependent. [Figure 7A] FIG. 1 shows that transferrin-binding protein enabled the movement of fused OVA across a monolayer of Caco-2 cells or through the intestinal epithelium via transcytosis. [Figure 7B] FIG. 1 shows that transferrin-binding protein enabled the movement of fused OVA across a monolayer of Caco-2 cells or through the intestinal epithelium via transcytosis. [Figure 7C] FIG. 1 shows that transferrin-binding protein enabled the movement of fused OVA across a monolayer of Caco-2 cells or through the intestinal epithelium via transcytosis. [Figure 8A] FIG. 1 shows that transferrin-binding protein enables associated OVA to cross the blood-brain barrier in mice, and the dependence of such ability is related to epitope access and affinity. [Figure 8B] FIG. 1 shows that transferrin-binding protein enables associated OVA to cross the blood-brain barrier in mice, and the dependence of such ability is related to epitope access and affinity. [Figure 8Ca] FIG. 1 shows that transferrin-binding protein enables associated OVA to cross the blood-brain barrier in mice, and the dependence of such ability is related to epitope access and affinity. [Figure 8Cb] FIG. 1 shows that transferrin-binding protein enables associated OVA to cross the blood-brain barrier in mice, and the dependence of such ability is related to epitope access and affinity. [Figure 8Cc] FIG. 1 shows that transferrin-binding protein enables associated OVA to cross the blood-brain barrier in mice, and the dependence of such ability is related to epitope access and affinity. [Figure 8Cd]FIG. 1 shows that transferrin-binding protein enables associated OVA to cross the blood-brain barrier in mice, and the dependence of such ability is related to epitope access and affinity. [Figure 8Ce] FIG. 1 shows that transferrin-binding protein enables associated OVA to cross the blood-brain barrier in mice, and the dependence of such ability is related to epitope access and affinity. [Figure 8Cf] FIG. 1 shows that transferrin-binding protein enables associated OVA to cross the blood-brain barrier in mice, and the dependence of such ability is related to epitope access and affinity. [Figure 9A] FIG. 1 shows intracellular delivery of transferrin binding protein-PE38 in various cells. [Figure 9B] FIG. 1 shows intracellular delivery of transferrin binding protein-PE38 in various cells. [Figure 10] FIG. 1 shows the biodistribution of transferrin binding protein mutants after systemic administration. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0047] While various embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions may occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the present invention described herein may be used.
[0048] In this application, the term "cell membrane" generally refers to the interface that separates various media and components inside and outside the cell in the cell structure. The plasma membrane is generally considered to be represented as a phospholipid bilayer embedded with the basic unit of phospholipid bilayer molecules, i.e., various types of membrane proteins, and sugars and glycolipids bound to the membrane proteins. Through the pores and certain properties of the transmembrane proteins, selective and controllable material transport can be achieved. For example, the cell membrane can belong to a polarized cell. For example, the cell membrane can belong to a non-polarized cell.
[0049] In this application, the term "polarized cells" generally refers to cells with stable asymmetry in structure and function, such as cells with resting potentials that are ready to transmit nerve impulse signals. The term "non-polarized cells" generally refers to cells with changes in resting potentials that transmit nerve impulse signals. For example, polarized cells and / or non-polarized cells may belong to the blood-brain barrier of the central nervous system. For example, polarized cells and / or non-polarized cells may belong to the intestinal epithelium. For example, polarized cells and / or non-polarized cells may belong to solid tissues.
[0050] In this application, the term "transferrin binding protein" generally refers to a protein that includes an antigen-binding portion, which can optionally adopt a scaffold or backbone portion in a conformation that facilitates binding of the antigen-binding protein to an antigen. For example, the antigen-binding protein can include, but is not limited to, an antibody, an antigen-binding fragment (Fab, Fab', F(ab)2, Fv fragment, F(ab')2, scFv, di-scFv and / or dAb), an immunoconjugate, a multispecific antibody (e.g., a bispecific antibody), an antibody fragment, an antibody derivative, an antibody analog, or a fusion protein, so long as it exhibits the desired antigen-binding activity. For example, the antigen-binding protein can be capable of specifically binding to transferrin. For example, the antigen-binding protein can not interfere with the interaction between transferrin and transferrin receptor 1. For example, the antigen-binding protein can not affect Tf / TfR1 binding. For example, the antigen-binding protein can maintain the normal physiological function of iron transport.
[0051] In this application, the term "transferrin" generally refers to a glycoprotein that can bind and transport multivalent ions. For example, transferrin can be a single-chain glycoprotein. For example, transferrin can have a molecular weight of about 77,000 D. For example, transferrin can have a polysaccharide. For example, transferrin can have two ion-binding sites. For example, the ion-binding sites can have different affinities with iron ions. For example, the multivalent ion can be an iron ion, a chromium ion, a manganese ion, a cadmium ion, or a nickel ion thereof. For example, each molecule of transferrin can bind to two trivalent iron atoms. For example, transferrin can be an iron-containing holotransferrin or an iron-free apotransferrin. For example, transferrin can be mouse transferrin. For example, the amino sequence of mouse transferrin can be as shown in GenBank: EDL21066.1, AAL34533.1, or AAL34533.1. For example, transferrin can be human transferrin. For example, the amino acid sequence of human transferrin can be as shown in GenBank: AAH59367.1, AAH59367.1, or AAB22049.1.
[0052] In the present application, the term "transferrin receptor" generally refers to a carrier protein of transferrin. For example, transferrin may be a transmembrane glycoprotein. For example, transferrin receptor may mediate endocytosis of transferrin associated with two iron ions. For example, transferrin receptor may maintain iron homeostasis in cells. For example, transferrin receptor may be transferrin receptor 1 (TfR1) or transferrin receptor 2 (TfR2). For example, TfR1 and TfR2 may show about 45-66% homology in the extracellular domain, but may exist in different expression patterns in the body. For example, TfR1 may have a higher affinity for transferrin than TfR2. For example, TfR2 may have a 25-fold lower affinity for transferrin compared to TfR1. For example, TfR2 may be expressed primarily in tissues involved in regulating iron metabolism, such as the liver and small intestine, while TfR1 is generally found on the surface of most somatic cells. The term "transferrin receptor 1" generally refers to a 97 kDa type 2 membrane protein expressed as a homodimer in cell membranes. TfR1-mediated transferrin internalization has classically been described as the canonical iron uptake pathway. For example, the transferrin receptor can be a mouse transferrin receptor. For example, the amino acid sequence of the mouse transferrin receptor can be as shown in GenBank: AAH54522.1, CAA40624.1, or NP_001344227.1. For example, the transferrin receptor can be a human transferrin receptor. For example, the amino acid sequence of the human transferrin receptor can be as shown in GenBank: AAA61153.1, AAF04564.1, or AAB19499.1.
[0053] In the present application, the term "half-life" generally refers to the time required for the serum concentration of an amino acid sequence, compound, or polypeptide to fall to a 50% level due to degradation of the sequence or compound by natural mechanisms and / or clearance or sequestration of the sequence or compound in the body. Half-life can be evaluated by methods known to those skilled in the art. The in vivo half-life of an amino acid sequence, compound, or polypeptide of the invention can be determined by any known method, for example by pharmacokinetic analysis. Suitable techniques are obvious to those skilled in the art, for example as described in WO 08 / 020079, page 57, paragraph o). As also mentioned in WO 08 / 020079, page 57, paragraph o), parameters such as t1 / 2-α, t1 / 2-β, and area under the curve (AUC) can be used to express half-life. In this regard, it should be noted that the term "half-life" in this application specifically refers to t1 / 2-β or terminal half-life (where t1 / 2-α and / or AUC can be ignored).See, for example, the experimental section and standard manuals such as Kenneth, A et al.: Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists and Peters et al., Pharmacokinete analysis: A Practical Approach (pharmacokinetics) Analysis: Practice Method) (1996).See also "Pharmacokinetics", M Gibaldi & D Perron, published by Marcel Dekker, 2nd edition, (1982).
[0054] In this application, the term "fusion protein" generally refers to a chimeric protein that contains the amino acid sequences of two or more different proteins, but the different proteins are not combined in their natural state, but rather their respective amino and carboxyl termini are joined via peptide bonds to form a continuous polypeptide. It should be understood that two or more different proteins may be directly joined via a peptide linker or spacer. For example, a fusion protein may contain a prophylactic or therapeutic agent fused to a heterologous protein, polypeptide, or peptide, where the heterologous protein, polypeptide, or peptide may or may not be a different type or therapeutic agent. For example, a fusion protein may contain two different proteins, polypeptides, or peptides that have immunomodulatory activity. For example, a fusion protein may retain or improve activity compared to the activity of the original polypeptide or protein. Typically, a fusion protein can be produced by in vitro recombinant techniques well known in the art. For example, a fusion protein may contain an antigen-binding protein. For example, a fusion protein may contain a biological molecule.
[0055] In this application, the term "blood-brain barrier (BBB)" generally refers to the physiological barrier between the peripheral circulation and the brain and spinal cord. It is formed by tight junctions in the plasma membrane of brain capillary endothelial cells and constitutes a strong barrier that limits the transport of molecules to the brain, even very small molecules such as urea (60 daltons). For example, brain capillary endothelial cells may have weaker pinocytosis. For example, the blood-brain barrier may include the BBB in the brain, the blood-spinal cord barrier in the spinal cord, and the blood-retina barrier in the retina. For example, the BBB may also include the blood-CSF barrier (choroid plexus), where the barrier is composed of ependymal cells instead of capillary endothelial cells.
[0056] In this application, the term "oral delivery of a drug" generally refers to a drug being absorbed into the blood by the digestive tract after oral administration, and reaching local or systemic tissues through the blood circulation to achieve the purpose of curing or preventing a disease. For example, the drug may include a transferrin binding protein. For example, the drug may include a biological molecule.
[0057] In this application, the term "associated entity" generally refers to any monomeric or multimeric protein, protein fragment, nucleotide sequence, small molecule compound, delivery vehicle, or modified transgene vector that is specifically linked to an antigen binding protein. Associated entities include, but are not limited to, antibodies and binding portions thereof, such as immunologically functional fragments. For example, the antigen binding protein can be a transferrin binding protein. In this application, the term "therapeutic entity" generally refers to any monomeric or multimeric protein or protein fragment that has the function of curing or preventing a disease.
[0058] In the present application, the term "heavy chain variable region (VH)" generally refers to a region of an immunoglobulin heavy chain structure that contains heavy chain complementarity determining regions CDR1, CDR2, CDR3 and framework regions FR1, FR2, FR3, FR4. The variable region of the heavy chain may contain a binding domain that interacts with an antigen. For example, the heavy chain variable region of the present application may contain a region that specifically binds to transferrin. For example, the heavy chain variable region of the present application may contain a VHH of a single domain antibody.
[0059] In this application, the terms "CDR" and "CDRs" generally refer to the complementarity determining regions (CDRs), three of which constitute the binding properties of the light chain variable region (LCDR1, LCDR2 and LCDR3) and three of which constitute the heavy chain variable region (HCDR1, HCDR2 and HCDR3). CDRs contribute to the functional activity of the antibody molecule and are separated by amino acid sequences that contain scaffold or framework regions. The precisely defined boundaries and lengths of CDRs are subject to various classification and numbering systems.
[0060] In this application, the terms "polypeptide", "peptide" and "protein" are used interchangeably to refer to a polymer of amino acid residues. The term also applies to amino acid polymers in which one or more amino acids are chemical analogs or modified derivatives of the corresponding naturally occurring amino acids. For example, a polypeptide can include an antigen binding protein and another molecule. For example, a polypeptide can include a fused antigen. For example, an antigen binding protein and a molecule can be linked directly or indirectly. For example, an antigen binding protein and a molecule can be linked via a linker. For example, a molecule can include a therapeutic molecule. For example, a molecule can include PE38. For example, a molecule can include GLP-1 or an analog.
[0061] In this application, the term "affinity" generally refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., a polypeptide or an antibody) and its binding partner (e.g., a target or an antigen). Unless otherwise specified, as used herein, "binding affinity" refers to the relationship between members of a binding pair (e.g., in a polypeptide-polynucleotide complex, or between a polypeptide and its target, or between an antibody and an antibody). The inherent binding affinity of a 1:1 interaction between antigens. The affinity of a molecule X for its partner Y can usually be expressed by a dissociation constant (Kd). Affinity can be measured by common methods known in the art, such as surface plasmon resonance, including the methods reported herein. A higher affinity of a molecule X for a binding partner Y can be seen in a lower Kd and / or EC50 value.
[0062] In this application, the term "isolated nucleic acid molecule" generally refers to a portion of a nucleic acid encoding a particular amino acid sequence, such as an antibody or antibody portion (e.g., VH, VL, CDR3) that selectively binds to transferrin, and means a nucleic acid sequence encoding a fusion protein with the antibody or antibody portion therein.
[0063] In this application, the term "vector" generally refers to a composition that contains an isolated nucleic acid and can be used to deliver the isolated nucleic acid to the inside of a cell. Many vectors are known in the art, including, but not limited to, linear polynucleotides, polynucleotides associated with ionic or amphiphilic compounds, plasmids, and viruses. Thus, the term "vector" includes autonomously replicating plasmids or viruses. The term should also be construed to include non-plasmid and non-viral compounds that facilitate the introduction of nucleic acids into cells, such as polylysine compounds, liposomes, and the like. Examples of viral vectors include, but are not limited to, adenoviral vectors, adeno-associated viral vectors, retroviral vectors, lentiviral vectors, and the like.
[0064] In this application, the term "cell" generally refers to a single cell, cell line, or cell culture that can be or has been a recipient of a nucleic acid molecule described in this application or a plasmid or vector of interest that includes a nucleic acid molecule described in this application. A cell can include the progeny of a single cell. Due to spontaneous, accidental, or deliberate mutations, the progeny may not necessarily be exactly the same as the original parent cell (in terms of the morphology of the total DNA complement or in the genome). A cell can include a cell that has been transfected in vitro with a vector described in this application.
[0065] In this application, the term "pharmaceutical composition" generally refers to a composition for preventing / treating a disease or condition. A pharmaceutical composition may include an antigen-binding protein, an immunoconjugate, an isolated nucleic acid molecule, a vector and / or a cell, and optionally a pharma-ceutically acceptable adjuvant. In addition, a pharmaceutical composition may also include one or more (pharmaceutically effective) carriers and other appropriate preparations. Acceptable components of a composition are preferably non-toxic to a recipient at the dosages and concentrations used. Pharmaceutical compositions of the present invention include, but are not limited to, liquid compositions, frozen compositions and lyophilized compositions.
[0066] Detailed Description of the Invention Transferrin-binding protein In certain aspects, the present application provides transferrin binding proteins that can specifically bind to transferrin and do not interfere with the interaction between transferrin and transferrin receptor 1.
[0067] For example, a transferrin binding protein may be able to extend the circulatory half-life of its associated entity.
[0068] For example, the half-life can be evaluated by methods known to those skilled in the art. For example, the in vivo half-life of the amino acid sequences, compounds or polypeptides of the present invention can be determined by any known method, for example by pharmacokinetic analysis. Suitable techniques are obvious to those skilled in the art, for example as described in paragraph o) on page 57 of WO 08 / 020079. As also mentioned in paragraph o) on page 57 of WO 08 / 020079, parameters such as t1 / 2-α, t1 / 2-β and area under the curve (AUC) can be used to express the half-life. In this regard, it should be noted that the term "half-life" in this application specifically refers to t1 / 2-β or terminal half-life (where t1 / 2-α and / or AUC can be ignored). See, for example, the following experimental sections and standard manuals, for example Kenneth, A et al.: Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists and Peters et al.
[0069] For example, the association entity can be any monomeric or multimeric protein, protein fragment, nucleotide sequence, small molecule compound, delivery vehicle, or modified transgene vector specifically linked to an antigen binding protein. For example, the association entity can include, but is not limited to, antibodies and binding portions thereof, such as immunologically functional fragments. For example, the antigen binding protein can be a transferrin binding protein.
[0070] For example, a transferrin binding protein may enable a fusion protein that includes the transferrin binding protein to cross the blood-brain barrier (BBB).
[0071] For example, the BBB may be a physiological barrier between the peripheral circulation and the brain and spinal cord. For example, the BBB may include the tight junctions of the plasma membrane of brain capillary endothelial cells, which constitute a strong barrier that limits the transport of molecules to the brain, even very small molecules such as urea (60 daltons). For example, brain capillary endothelial cells may have weaker pinocytosis. For example, the blood-brain barrier may include the BBB in the brain, the blood-spinal cord barrier in the spinal cord, and the blood-retina barrier in the retina. For example, the BBB may also include the blood-CSF barrier (choroid plexus), where the barrier is composed of ependymal cells instead of capillary endothelial cells.
[0072] For example, the fusion protein can enter brain tissue by crossing the BBB.
[0073] For example, transferrin binding proteins can be used for oral delivery of drugs.
[0074] For example, the dosage form for oral delivery of the drug may be a capsule, granules, or tablet.
[0075] For example, a transferrin binding protein can enable intracellular delivery of its associated entity to a transferrin receptor expressing cell.
[0076] For example, a transferrin binding protein can specifically bind to transferrin and not interfere with the interaction between transferrin and transferrin receptor 1.
[0077] For example, the transferrin can be human transferrin.
[0078] For example, the transferrin can be iron-containing holotransferrin.
[0079] For example, iron-containing holotransferrin is a mixture of transferrin and Fe 3+ may include.
[0080] For example, transferrin contains Fe3+ can bind to
[0081] For example, transferrin contains two Fe 3+ can bind to
[0082] For example, iron-containing holo-transferrin can bind to the transferrin receptor.
[0083] For example, iron-containing holo-transferrin can bind to the transferrin receptor 1.
[0084] For example, iron-containing holo-transferrin can be transported to endosomes by the transferrin receptor.
[0085] For example, iron-containing holo-transferrin can be transported through endocytosis.
[0086] For example, iron-containing holo-transferrin can be transported through transcytosis.
[0087] For example, iron-containing holotransferrin is Fe 3+ It can be separated from
[0088] For example, the transferrin can be iron-free apotransferrin.
[0089] For example, iron-free apotransferrin contains Fe 3+ The iron-containing holotransferrin may be derived from iron-containing holotransferrin isolated from
[0090] For example, iron-free apotransferrin contains Fe 3+ may be able to bind to
[0091] For example, a transferrin binding protein can have a higher affinity for iron-containing holotransferrin than for iron-free apotransferrin.
[0092] For example, affinity can be measured by a surface plasmon resonance-based assay.
[0093] For example, affinity can be measured by enzyme-linked immunosorbent assay (ELISA).
[0094] For example, affinity can be measured by a competitive assay (RIA).
[0095] For example, affinity can be measured by flow cytometry (FACS).
[0096] For example, affinity can be expressed as a binding equilibrium constant (KD).
[0097] For example, the affinity of a transferrin binding protein for iron-containing holotransferrin can be 2-fold, 4-fold, 6-fold, 8-fold, 10-fold, 20-fold, 40-fold, 60-fold, 80-fold, 100-fold higher than its affinity for iron-free apotransferrin.
[0098] For example, the transferrin binding protein can include a monoclonal antibody.
[0099] For example, the transferrin binding protein can include a single chain antibody fragment.
[0100] For example, the transferrin binding protein can include a single domain antibody fragment.
[0101] For example, the transferrin binding protein can include an engineered protein.
[0102] For example, the transferrin binding protein can include a peptide.
[0103] For example, an antibody or antibody fragment to a transferrin binding protein can include an animal-derived sequence.
[0104] For example, an antibody or antibody fragment to a transferrin binding protein can include humanized sequences.
[0105] For example, an antibody or antibody fragment to a transferrin binding protein can include fully human sequences.
[0106] For example, an antibody or antibody fragment to a transferrin binding protein can include chimeric sequences.
[0107] For example, an antibody or antibody fragment to a transferrin binding protein can include a synthetic sequence.
[0108] For example, the antibody or antibody fragment to a transferrin binding protein may be a single domain antibody fragment, VHH.
[0109] In the present application, the transferrin binding protein may comprise at least one CDR in the heavy chain variable region VH, and the VH comprises the amino acid sequence shown in any of SEQ ID NOs: 70 to 104.
[0110] For example, VH may comprise the amino acid sequence shown in any one of SEQ ID NOs:70-104.
[0111] For example, the transferrin binding protein may comprise an HCDR3 of a VH having an amino acid sequence shown in any one of SEQ ID NOs:45-69.
[0112] For example, the transferrin-binding protein may comprise an HCDR2 of a VH having an amino acid sequence shown in any one of SEQ ID NOs:22-44.
[0113] For example, the transferrin-binding protein may comprise an HCDR1 of a VH having an amino acid sequence shown in any one of SEQ ID NOs: 1-21.
[0114] For example, a transferrin binding protein may comprise HCDR1, HCDR2, and HCDR3, where HCDR1 may comprise the amino acid sequence shown in any one of SEQ ID NOs: 1 to 21, HCDR2 may comprise the amino acid sequence shown in any one of SEQ ID NOs: 22 to 44, and HCDR3 may comprise the amino acid sequence shown in any one of SEQ ID NOs: 45 to 69.
[0115] For example, the transferrin binding protein can include an Fc region.
[0116] For example, the Fc region can comprise a human Fc region.
[0117] For example, the Fc region can include a human IgG Fc region.
[0118] For example, the Fc region can comprise a human IgG1 Fc region. For example, the Fc region can comprise a human IgG4 Fc region.
[0119] For example, the transferrin binding protein may comprise an antibody or an antigen-binding fragment thereof. The antibody may be selected from the group consisting of a monoclonal antibody, a single chain antibody, a chimeric antibody, a multispecific antibody, a humanized antibody, and a fully human antibody. The antigen-binding fragment is selected from the group consisting of a Fab, a Fab', a F(ab)2, a F(ab')2, a sdAb, a Fv, a dAb, and a ScFv fragment.
[0120] For example, the transferrin binding protein may be a VHH.
[0121] For example, the VHH may comprise a CDR3, and the CDR3 may comprise an amino acid sequence shown in any one of SEQ ID NOs: 45-69.
[0122] For example, the VHH may comprise CDR2, and the CDR2 may comprise the amino acid sequence shown in any one of SEQ ID NOs: 22-44.
[0123] For example, VHH may comprise CDR1, and CDR1 may comprise the amino acid sequence shown in any one of SEQ ID NOs: 1-21.
[0124] For example, a VHH may comprise CDR1, CDR2, and CDR3, where CDR1 may comprise the amino acid sequence shown in any one of SEQ ID NOs: 1 to 21, CDR2 may comprise the amino acid sequence shown in any one of SEQ ID NOs: 22 to 44, and CDR3 may comprise the amino acid sequence shown in any one of SEQ ID NOs: 45 to 69.
[0125] For example, a VHH may comprise CDR1, CDR2, and CDR3, and CDR1, CDR2, and CDR3 may comprise the amino acid sequences set forth in SEQ ID NO:1, SEQ ID NO:22, and SEQ ID NO:45, respectively; or CDR1, CDR2, and CDR3 may comprise the amino acid sequences set forth in SEQ ID NO:1, SEQ ID NO:22, and SEQ ID NO:63, respectively; or CDR1, CDR2, and CDR3 may comprise the amino acid sequences set forth in SEQ ID NO:2, SEQ ID NO:23, and SEQ ID NO:46, respectively; or CDR1, CDR2, and CDR3 may comprise the amino acid sequences set forth in SEQ ID NO:1, SEQ ID NO:23, and SEQ ID NO:46, respectively; or CDR1, CDR2, and CDR3 may comprise the amino acid sequences shown in SEQ ID NO:2, SEQ ID NO:40, and SEQ ID NO:58, respectively; or CDR1, CDR2, and CDR3 may comprise the amino acid sequences shown in SEQ ID NO:2, SEQ ID NO:41, and SEQ ID NO:58, respectively; or CDR1, CDR2, and CDR3 may comprise the amino acid sequences shown in SEQ ID NO:2, SEQ ID NO:23, and SEQ ID NO:66, respectively; or CDR1, CDR2, and CDR3 may comprise the amino acid sequences shown in SEQ ID NO:2, SEQ ID NO:23, and SEQ ID NO:66, respectively; or CDR1, CDR2, and CDR3 may comprise the amino acid sequences set forth in SEQ ID NO:3, SEQ ID NO:24, and SEQ ID NO:47, respectively; or CDR1, CDR2, and CDR3 may comprise the amino acid sequences set forth in SEQ ID NO:4, SEQ ID NO:25, and SEQ ID NO:48, respectively; or CDR1, CDR2, and CDR3 may comprise the amino acid sequences set forth in SEQ ID NO:5, SEQ ID NO:26, and SEQ ID NO:49, respectively; or CDR1, CDR2, and CDR3 may comprise the amino acid sequences set forth in SEQ ID NO:6, SEQ ID NO:27, and SEQ ID NO:50 ... CDR1, CDR2, and CDR3 may comprise the amino acid sequences set forth in SEQ ID NO:6, SEQ ID NO:27, and SEQ ID NO:59, respectively; or CDR1, CDR2, and CDR3 may comprise the amino acid sequences set forth in SEQ ID NO:7, SEQ ID NO:28, and SEQ ID NO:51, respectively; or CDR1, CDR2, and CDR3 may comprise the amino acid sequences set forth in SEQ ID NO:8, SEQ ID NO:29, and SEQ ID NO:52, respectively; or CDR1, CDR2, and CDR3 may comprise the amino acid sequences set forth in SEQ ID NO:9, SEQ ID NO:30, and SEQ ID NO:53, respectively;or CDR1, CDR2 and CDR3 may comprise the amino acid sequences set forth in SEQ ID NO:10, SEQ ID NO:31 and SEQ ID NO:54, respectively; or CDR1, CDR2 and CDR3 may comprise the amino acid sequences set forth in SEQ ID NO:11, SEQ ID NO:32 and SEQ ID NO:55, respectively; or CDR1, CDR2 and CDR3 may comprise the amino acid sequences set forth in SEQ ID NO:12, SEQ ID NO:33 and SEQ ID NO:56, respectively; or CDR1, CDR2 and CDR3 may comprise the amino acid sequences set forth in SEQ ID NO:13, SEQ ID NO:34 and SEQ ID NO:57, respectively; or CDR1, CDR2 and CDR3 may comprise the amino acid sequences set forth in SEQ ID NO:14, SEQ ID NO:35 and SEQ ID NO:60, respectively; or CDR1, CDR2 and CDR3 may comprise the amino acid sequences set forth in SEQ ID NO:15, SEQ ID NO:36 and SEQ ID NO:61, respectively; or CDR1, CDR2, and CDR3 may comprise the amino acid sequences shown in SEQ ID NO: 16, SEQ ID NO: 37, and SEQ ID NO: 62, respectively; or CDR1, CDR2, and CDR3 may comprise the amino acid sequences shown in SEQ ID NO: 17, SEQ ID NO: 38, and SEQ ID NO: 64, respectively; or CDR1, CDR2, and CDR3 may comprise the amino acid sequences shown in SEQ ID NO: 18, SEQ ID NO: 39, and SEQ ID NO: 65, respectively; or CDR1, CDR2, and CDR3 may comprise the amino acid sequences shown in SEQ ID NO: 19, SEQ ID NO: 42, and SEQ ID NO: 67, respectively; or CDR1, CDR2, and CDR3 may comprise the amino acid sequences shown in SEQ ID NO: 20, SEQ ID NO: 43, and SEQ ID NO: 68, respectively; or CDR1, CDR2, and CDR3 may comprise the amino acid sequences shown in SEQ ID NO: 21, SEQ ID NO: 44, and SEQ ID NO: 69, respectively.
[0126] For example, the VHH may comprise an amino acid sequence shown in any one of SEQ ID NOs: 70 to 104. For example, SLN9056 comprises an amino acid sequence shown in SEQ ID NO: 70. For example, SLN9057 comprises an amino acid sequence shown in SEQ ID NO: 71. For example, SLN0042 comprises an amino acid sequence shown in SEQ ID NO: 72. For example, SLN0043 comprises an amino acid sequence shown in SEQ ID NO: 73. For example, SLN0044 comprises an amino acid sequence shown in SEQ ID NO: 74. For example, SLN0045 comprises an amino acid sequence shown in SEQ ID NO: 75. For example, SLN0049 comprises an amino acid sequence shown in SEQ ID NO: 76. For example, SLN0056 comprises an amino acid sequence shown in SEQ ID NO: 77. For example, SLN0057 comprises an amino acid sequence shown in SEQ ID NO: 78. For example, SLN0059 comprises an amino acid sequence shown in SEQ ID NO: 79. For example, SLN0062 comprises an amino acid sequence shown in SEQ ID NO: 80. For example, SLN0064 comprises the amino acid sequence shown in SEQ ID NO: 81. For example, SLN0065 comprises the amino acid sequence shown in SEQ ID NO: 82. For example, SLN0071 comprises the amino acid sequence shown in SEQ ID NO: 83. For example, SLN0072 comprises the amino acid sequence shown in SEQ ID NO: 84. For example, SLN0046 comprises the amino acid sequence shown in SEQ ID NO: 85. For example, SLN0058 comprises the amino acid sequence shown in SEQ ID NO: 86. For example, SLN9008 comprises the amino acid sequence shown in SEQ ID NO: 87. For example, SLN9013 comprises the amino acid sequence shown in SEQ ID NO: 88. For example, SLN9015 comprises the amino acid sequence shown in SEQ ID NO: 89. For example, SLN9025 comprises the amino acid sequence shown in SEQ ID NO: 90. For example, SLN9026 comprises the amino acid sequence shown in SEQ ID NO: 91. For example, SLN9056 comprises the amino acid sequence shown in SEQ ID NO: 70.
[0127] The antigen-binding protein of the present application may bind to Tf in competition with a reference antibody, the reference antibody may comprise a heavy chain variable region and a light chain variable region, the heavy chain variable region of the reference antibody may comprise HCDR1, HCDR2 and HCDR3, HCDR1 may comprise the amino acid sequence shown in any one of SEQ ID NOs: 1 to 21, HCDR2 may comprise the amino acid sequence shown in any one of SEQ ID NOs: 22 to 44, and HCDR3 may comprise the amino acid sequence shown in any one of SEQ ID NOs: 45 to 69.
[0128] Polypeptides In another aspect, the present application provides a polypeptide comprising a transferrin binding protein.
[0129] For example, the polypeptide may comprise a therapeutic entity.
[0130] For example, the therapeutic entity can be an engineered cytotoxic Pseudomonas exotoxin A (PE38). For example, PE38 can include the amino acid sequence set forth in SEQ ID NO:109.
[0131] For example, the therapeutic entity can be glucagon-like peptide-1 (GLP-1) or a variant thereof. For example, the GLP-1 can include the amino acid sequence shown in SEQ ID NO:108.
[0132] For example, a variant may be a polypeptide that has significant sequence identity with the parent polypeptide and retains the biological activity of the parent polypeptide. For example, the amino acid sequence of the variant may have at least about 50%, 75%, 80%, 90%, 95%, 96%, 97%, 98%, 98.2%, 98.4%, 98.6%, 98.8%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or more identity with the amino acid sequence of the parent polypeptide. For example, a variant may also be a protein or polypeptide in which one or more amino acids have been substituted, deleted or added to the amino acid sequence of the protein and / or polypeptide. For example, a variant can include a protein or polypeptide having at least one, such as 1-30, 1-20 or 1-10, and also such as 1, 2, 3, 4 or 5 amino acid substitutions, deletions and / or insertions resulting in an amino acid change. For example, the substitutions can be conservative.
[0133] For example, the therapeutic entity and the transferrin binding protein can be directly linked.
[0134] For example, the therapeutic entity and the transferrin binding protein can be linked through gene fusion or recombinant DNA techniques.
[0135] For example, the therapeutic entity and the transferrin binding protein can be indirectly linked.
[0136] For example, the therapeutic entity and the transferrin binding protein can be linked through a spacer.
[0137] For example, the therapeutic entity and the transferrin binding protein can be linked through a linker.
[0138] For example, the linker can be a peptide having an amino acid sequence.
[0139] For example, the linker may be of synthetic origin.
[0140] Isolated nucleic acid molecules, vectors and cells In another aspect, the application provides one or more isolated nucleic acid molecules encoding an isolated transferrin binding protein or polypeptide of the application.
[0141] The nucleic acid molecules of the present application can be isolated. For example, they can be produced or synthesized by: (i) amplified in vitro, e.g., produced by polymerase chain reaction (PCR) amplification, (ii) produced by cloning and recombination, (iii) purified, e.g., by enzymatic digestion and gel electrophoretic fractionation, or (iv) synthesized, e.g., chemically synthesized. In certain embodiments, an isolated nucleic acid is a nucleic acid molecule prepared by recombinant DNA technology.
[0142] In the present application, nucleic acids encoding antibodies or antigen-binding fragments thereof can be prepared by a variety of methods known in the art, including but not limited to restriction fragment manipulation or overlap extension PCR using synthetic oligonucleotides.
[0143] In another aspect, the present application provides a vector that can include the nucleic acid molecule of the present application.
[0144] In another aspect, the present application provides one or more vectors comprising one or more nucleic acid molecules of the present application. Each vector may contain one or more nucleic acid molecules. In addition, the vector may also contain other genes, such as marker genes that allow the selection of the vector in a suitable host cell and under suitable conditions. In addition, the vector may also contain expression control elements that allow the correct expression of the coding region in a suitable host. Such control elements are well known to those skilled in the art and may include, for example, promoters, ribosome binding sites, enhancers, and other control elements that regulate gene transcription or mRNA translation. One or more nucleic acid molecules of the present application may be operably linked to expression control elements. The vector may include, for example, a plasmid, cosmid, virus, phage, or other vectors commonly used, for example, in genetic engineering. For example, the vector is an expression vector.
[0145] In another aspect, the present application provides a cell that can include the nucleic acid molecule of the present application or the vector of the present application.
[0146] In another aspect, the present application provides a host cell that can contain one or more of the nucleic acid molecules of the present application and / or one or more of the vectors of the present application.
[0147] In certain embodiments, each type or each host cell may contain one or one type of nucleic acid molecule or vector of the present application. In certain embodiments, each type or each host cell may contain multiple (e.g., two or more) or multiple types (e.g., two or more) of nucleic acid molecules or vectors of the present application. For example, a vector of the present application may be introduced into a host cell, such as a eukaryotic cell, such as a cell derived from a plant, a fungal cell, or a yeast cell. A vector of the present application may be introduced into a host cell by methods known in the art, such as electroporation, lipofectin transfection, lipofectamine transfection, etc.
[0148] Pharmaceutical Compositions In another aspect, the present application provides a pharmaceutical composition, which can include a transferrin binding protein of the present application, a nucleic acid molecule of the present application, a vector of the present application, and / or a cell of the present application, and optionally a pharma- ceutically acceptable adjuvant.
[0149] For example, the pharmaceutical compositions of the present application may be used directly for therapy or diagnosis, and therefore for preventing and treating diseases. In addition, other therapeutic entities may be used simultaneously.
[0150] The pharmaceutical composition of the present application may contain a safe and effective amount (e.g., 0.001-99% by weight, 0.01-90% by weight, or 0.1-80% by weight) of the transferrin-binding protein of the present application and a pharma- ceutically acceptable adjuvant (which may include a carrier or excipient). Such carriers may include, but are not limited to, saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. The pharmaceutical preparation should be consistent with the mode of administration. The pharmaceutical composition of the present application may be in the form of an injectable solution, which may be prepared by conventional methods using, for example, saline or an aqueous solution containing glucose and other adjuvants. The pharmaceutical composition, such as an injectable solution or solution, should be manufactured under sterile conditions. The dosage of the active ingredient is a therapeutically effective amount. In addition, the transferrin-binding protein of the present application may also be used with other therapeutic entities.
[0151] The transferrin binding proteins or pharmaceutical compositions described herein may be formulated, administered, and administered in a manner consistent with the principles of good medical practice. Considerations in this case include the specific condition being treated, the specific mammal being treated, the clinical symptoms of the individual patient, the etiology of the condition, the site of drug delivery, the method of administration, and other factors known to medical practitioners. The therapeutic entity is optionally, but need not be, formulated together with and / or administered simultaneously with one or more entities currently used to prevent or treat the condition under consideration. The effective amount of such other entities will depend on the amount of therapeutic agent present in the preparation, the type of condition or treatment, and other factors discussed above. In general, these entities may be used in any dose empirically / clinically determined as necessary, and by any route empirically / clinically determined as necessary. Compared to monotherapy, the dose of the antibody administered in the combination therapy may be reduced. It is easy to monitor the progress of this therapy by conventional techniques.
[0152] method In another aspect, the application provides a method for translocating molecules across a cell membrane by using transferrin binding proteins.
[0153] For example, the methods may be used for drug delivery across cell membranes.
[0154] For example, the cell membrane may belong to a polarized cell.
[0155] For example, a polarized cell can be a functional cell.
[0156] For example, the polarized cell can be a neuronal cell.
[0157] For example, the cell membrane may belong to a non-polarized cell.
[0158] For example, the non-polarized cell can be a neuronal cell.
[0159] For example, non-polarized cells can transmit neural signals.
[0160] For example, polarized and / or non-polarized cells may express the transferrin receptor on their cell membrane.
[0161] For example, polarized and / or non-polarized cells may express the human transferrin receptor on their cell membrane.
[0162] For example, polarized and / or non-polarized cells may express transferrin receptor 1.
[0163] For example, polarized and / or non-polarized cells may express human transferrin receptor 1.
[0164] For example, non-polarized cells may reside at the blood-brain barrier.
[0165] For example, the non-polarized cells may belong to the intestinal epithelium.
[0166] For example, non-polarized cells may reside in multiple layers of cells in a solid tissue.
[0167] In this application, methods of drug delivery across cell membranes may include crossing the blood-brain barrier, crossing the intestinal epithelium, crossing multiple layers of cells in solid tissues, intracellular delivery of drugs, and / or recycling of endocytosed drugs back into the circulation.
[0168] For example, drug delivery across cell membranes may occur in non-polarized cells.
[0169] For example, drug delivery across a cell membrane can include crossing the blood-brain barrier for systemically administered drugs targeted to the central nervous system.
[0170] For example, drug delivery across a cell membrane may include the crossing of the intestinal epithelium of an orally administered drug.
[0171] For example, drug delivery across cell membranes can involve permeation of a drug through multiple layers of cells in solid tissue.
[0172] For example, drug delivery across cell membranes may occur in polarized cells.
[0173] For example, drug delivery across a cell membrane can include intracellular delivery of the drug.
[0174] For example, drug delivery across a cell membrane may involve recycling of endocytosed drug back into the circulation.
[0175] For example, the drug may include a small molecule compound.
[0176] For example, a small molecule compound can be a chemically synthesized drug.
[0177] For example, the molecular weight of a small molecule compound may be less than 1000 Daltons.
[0178] For example, small molecule compounds can have therapeutic effects.
[0179] For example, small molecule compounds may have anti-tumor activity.
[0180] For example, the drug may include a synthetic peptide.
[0181] For example, the synthetic peptides may include α-amino acids.
[0182] For example, the α-amino acids can be linked through a peptide chain.
[0183] For example, synthetic peptides can be synthesized through solid phase peptide synthesis.
[0184] For example, synthetic peptides can be synthesized through liquid phase peptide synthesis.
[0185] For example, the drug may include a recombinant protein.
[0186] For example, a recombinant protein can be a polypeptide of semi-synthetic or synthetic origin.
[0187] For example, recombinant proteins can be expressed by joining DNA molecules from different sources using recombinant DNA techniques.
[0188] For example, a recombinant protein may no longer be fully or partially associated with the protein in its natural state.
[0189] For example, a recombinant protein may be linked to a peptide other than the peptide to which it is naturally linked.
[0190] For example, a recombinant protein may not be present in the natural state.
[0191] For example, the drug may comprise an antibody. For example, the drug may comprise an antibody fragment.
[0192] For example, the antigen fragment can be a Fab, Fab', F(ab)2, Fv fragment, F(ab')2, scFv, di-scFv and / or a dAb.
[0193] For example, the drug may include an enzyme.
[0194] For example, an enzyme can be a catalytically active protein.
[0195] For example, the drug may comprise a portion of a nucleotide acid sequence.
[0196] For example, the nucleotide acid sequence can be a DNA sequence.
[0197] For example, the nucleotide sequence can be an RNA sequence.
[0198] For example, the nucleotide sequence can be genomic DNA, cDNA, synthetic DNA, proviral DNA, viral DNA, mRNA, synthetic RNA or a combination thereof.
[0199] For example, the nucleotide sequence may encode a peptide or protein.
[0200] For example, synthetic RNA may modulate mRNA stability or translation.
[0201] For example, the synthetic RNA can be a small interfering RNA (siRNA) or an antisense oligo (ASO).
[0202] For example, the drug may comprise a liposome.
[0203] For example, a liposome can be a vesicle made up of one or more layers of concentrically arranged lipid bilayers.
[0204] For example, the liposomes may include an aqueous phase.
[0205] For example, the aqueous phase may contain nucleic acids.
[0206] For example, the drug may comprise a nano-sized particle, such as a lipid nanoparticle.
[0207] For example, a lipid nanoparticle can contain multiple lipid molecules physically bound to one another by intermolecular forces.
[0208] For example, the intermolecular forces can be covalent or non-covalent.
[0209] For example, the lipid nanoparticles can include one or more lipids.
[0210] For example, the lipids can be cationic lipids, non-cationic lipids and PEG-lipids.
[0211] For example, the drug may include a drug vehicle.
[0212] For example, the drug vehicle can be a standard composition suitable for human administration.
[0213] For example, the drug vehicle may be a typical adjuvant used in animal vaccination.
[0214] For example, the drug may include a modified virus.
[0215] For example, the modified virus can be a genetically engineered virus.
[0216] For example, the modified viruses may inhibit the growth of cancerous or hyperproliferative cells in vivo or in vitro.
[0217] For example, the modified viruses may induce death in cancerous or hyperproliferative cells in vivo or in vitro.
[0218] For example, the modified virus can be an oncolytic virus.
[0219] For example, the drug may comprise a gene therapy vector.
[0220] For example, a gene therapy vector may be capable of delivering a target gene to a target cell.
[0221] For example, a target gene can be released into a target cell.
[0222] For example, the target gene may be integrated into the nucleus.
[0223] For example, gene therapy vectors can exert the therapeutic function of targeted genes.
[0224] For example, the gene therapy vector can be a plasmid vector, a phage vector, a viral vector or a non-viral vector thereof.
[0225] For example, the gene therapy vector can be a cloning vector or an expression vector.
[0226] For example, the gene therapy vector can be a temperature sensitive vector, a fusion expression vector or a non-fusion expression vector.
[0227] For example, the drug can be associated with a transferrin binding protein.
[0228] For example, a drug can be conjugated to a transferrin binding protein through gene fusion.
[0229] For example, a drug can be associated with a transferrin binding protein through chemical conjugation.
[0230] For example, the methods may be used to extend the circulation half-life of a therapeutic entity.
[0231] For example, the therapeutic entity can be linked directly or indirectly to a transferrin binding protein.
[0232] For example, the methods can be used to deliver therapeutic agents comprising or using transferrin binding entities to cells or organs expressing the transferrin receptor.
[0233] For example, the methods include using transferrin binding entities and can be used to deliver targeted drugs across the blood-brain barrier, intestinal epithelium, and / or cell membranes that express the transferrin receptor.
[0234] For example, the method may be used for oral delivery of a therapeutic or diagnostic entity, where the therapeutic or diagnostic entity is linked to an antigen binding protein.
[0235] For example, the method may be used for intracellular delivery of a therapeutic entity, where the therapeutic entity is directly or indirectly linked to an antigen binding protein. EXAMPLES
[0236] The following examples are presented to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention, and are not intended to limit the scope of what the inventors regard as the invention, nor are they intended to represent that the following experiments are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.), but some experimental error and deviation should be accounted for. Unless otherwise indicated, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Celsius, and pressure is at or near atmospheric. Standard abbreviations may be used, such as bp, base pairs; kb, kilobases; pl, picoliters; s or sec, seconds; min, minutes; h or hr, hours; aa, amino acids; nt, nucleotides; CPU, colony forming units; rpm, revolutions per minute; RT, room temperature; im, intramuscular; ip, intraperitoneal; sc, subcutaneous; and the like.
[0237] Example 1. Establishment of a VHH immune library Two healthy, age-appropriate camels were immunized four times with human transferrin (human transferrin, Sigma T3309). After checking the antibody titer eligibility, 200 ml of peripheral blood was collected from each, lymphocytes were isolated, and total RNA was extracted. Reverse transcription was applied to generate cDNA for constructing a phage-displayed camel immune VHH antibody library. To confirm the quality of the VHH antibody library, 24 independent phage clones were subjected to DNA sequencing. The data showed that 22 of the 24 clones contained the canonical VHH sequence fused to the gp3 protein used for phage display, and each of the 22 clones had a unique VHH sequence with a CDR3 of 9 amino acids or more in length. This library was used for subsequent antibody discovery.
[0238] Example 2 VHH discovery 2.1-Panning The phage library was removed from the -80°C freezer, incubated at 37°C for 10 minutes, and centrifuged at 5000 rpm for 5 minutes. 12 ~1013 CFU phage (input) were transferred to 1 mL of PBS solution containing 1% BSA, 10 μg of biotinylated human or mouse transferrin protein in a microtube. The mixture was incubated at room temperature for 1 h, and then 100 μL of streptavidin-coated magnetic Dyna bead suspension was added. After 30 min of incubation at room temperature on a rotating tumbler, the solution mixture was removed by placing the tube on a magnetic rack for 30 s. The beads were washed 10 times with 1 mL of PBST (0.05% Tween 20 in PBS, pH 7.4), followed by a final wash with PBS.
[0239] Phages were eluted from the beads with 1 mL of 10 μg / mL trypsin in PBS by incubating at 37° C. for 30 min and separated from the beads on a magnetic rack. The supernatant (output) was transferred to a tube containing 4 mL of TG1 (A600 approx. 0.6) to infect bacteria. After incubation at 37° C. for 30 min, the infected bacteria were harvested by centrifugation at 4,500 rpm for 10 min at 4° C. The pellet was resuspended in 500 μL and spread on a 25×25 cm 2×YT / Amp / Glu plate to amplify the phage-infected bacteria. After overnight incubation at 37° C., the bacteria were scraped off the plate by adding 30 mL of 2×YT medium and harvested by centrifugation at 4,500 rpm for 10 min. Resuspend the pellet by adding 2 mL of 2xYT medium containing 40% glycerol to have stocks at -80°C or directly prepare phages for the next round of panning if desired (as below in phage preparation or packaging).
[0240] The input and output phages were also titrated to determine the phage enrichment efficiency of the panning process. Briefly, serial dilutions (10-fold, typically 10) of the input / output phages in PBS were -1 ~10 -9) was prepared and 10 μL of serially diluted phage was mixed with 90 μL of log-phase TG1 in a new tube and then incubated at 37°C for 30 min. Then, 10 μL of the mixture was spotted onto a pre-warmed 2×YT / Amp plate. After opening the lid to allow the solution to evaporate, the bacterial plate was incubated overnight at 37°C. Colonies were counted and titers were calculated for input and output phages, respectively, and the output / input ratio from each panning round was used to determine the efficiency of the panning process.
[0241] 2.2 Phage preparation or packaging Phage-infected TG1 bacteria were inoculated into 2xYT / Amp / Glu medium at 37°C with shaking (250 rpm) and allowed to reach an A600 of 0.6 (approximately 1-2 hours). Helper phage M13K07 was added at a phage:bacteria ratio of 1000. Cultures were incubated at 37°C for 30 minutes without shaking, followed by 30 minutes with shaking at 180 rpm.
[0242] The bacterial culture was centrifuged in a sterile centrifuge bottle at 4,500 rpm for 10 min to collect the bacterial pellet, which was resuspended in 100 mL of 2xYT / Amp / Kan (Amp: 100 μg / mL, Kan: 50 μg / mL) and transferred to a 250 mL flask for incubation at 37°C with shaking (250 rpm) for 4 h.
[0243] The culture was centrifuged at 4,500 rpm for 10 min to collect the supernatant. Phages were precipitated from the supernatant by adding ¼ volume of PEG solution (20% polyethylene glycol 6000, 2.5 M NaCl) and incubating on ice overnight. After recovery by centrifugation at 4,500 rpm for 30 min at 4°C, the phage pellet was resuspended in 5 mL of PBS and incubated at 37°C for 30 min with shaking. Insoluble debris was removed by centrifugation at 4,500 rpm for 10 min, and the soluble phage in the supernatant was transferred to a new tube to repeat the PEG precipitation once. The final phage solution in PBS was used for the next round of panning or mixed with glycerol for storage at 80°C.
[0244] 2.3 Phage-based ELISA screening Single colonies from the panning output were individually picked from the agar plates and inoculated into 2xYT / GA medium (2% glucose, 100 μg / mL ampicillin) in 96-well deep-well plates overnight at 37 °C with a shaking speed of 320 rpm. 10 μL of the overnight culture was transferred to 400 μL of 2YT / GA medium in a new deep-well plate. The culture was grown at 37 °C with shaking (800 rpm) until the A600 was 0.6 (approximately 1 h) and then inoculated with helper phage M13K07 (4.2 × 10 13 CFU / mL) was added at a phage:bacteria ratio of 1000 (100 μL in 100 mL). The culture was continued to incubate at 37°C for 30 min without shaking, followed by 30 min with shaking at 180 rpm. The bacterial culture was centrifuged at 4,000 rpm for 30 min and the supernatant was discarded. The bacterial pellet was resuspended in 400 μL of 2×YT / AK (Amp: 100 μg / mL, Kan: 50 μg / mL) and incubated overnight at 30°C with shaking (320 rpm). The bacterial culture was centrifuged at 4,000 rpm for 30 min to collect the supernatant. The supernatant was used as the phage solution for ELISA screening.
[0245] To perform ELISA screening, 96-well microtiter plates were coated with 100 μL per well of streptavidin at a concentration of 1 μg / mL (carbonate buffered saline or CBS, pH 9.4) overnight at 4° C. Each well was blocked with 200 μL of blocking buffer (PBS pH 7.4 / 0.05% Tween 20 / 1% BSA) for 1 h at room temperature. After washing the wells three times with PBST (PBS / 0.05% Tween 20, pH 7.4), 100 μL of biotinylated human or mouse transferrin protein (1 μg / mL in blocking buffer) was added and incubated for 1 h at room temperature. After washing the wells three times with PBST, 100 μL of phage solution (above) was added and incubated for 1 h at room temperature. The wells were washed three times with PBST, and 100 μL of mouse anti-M13 IgG-HRP (prepared in blocking buffer) was added to each well and incubated for 1 h at room temperature. The wells were washed three times with PBST, and 100 μL of TMB solution was added and incubated for 15 min at room temperature in the dark. After terminating the reaction with 100 μL of stop solution, the plate was scanned at 450 nm. Positive clones with specific binding to transferrin were selected for DNA sequencing to identify unique VHHs on the deduced amino acid sequence.
[0246] 2.4 Production of recombinant VHH-OVA-his protein Unique VHH clones were selected for subcloning to generate recombinant plasmids to produce VHH-OVA-His protein (OVA contains the amino acid sequence shown in SEQ ID NO: 107). After the plasmid sequence was verified by sequencing, small-scale production of the recombinant protein was performed using transient transfection of HEK293 cells with the recombinant plasmids using lipofectamine or PEI as transfection reagents. Cultures were grown for 5-7 days in shake flask medium at a scale ranging from 30 ml to 100 ml. Cells were removed by centrifugation and culture supernatants were used for protein purification by Ni-NTA Sepharose. Purified proteins were analyzed on 4-12% gradient SDS-PAGE gels under non-reducing or reducing conditions (Figure 1).
[0247] 2.5 Transferrin binding assay To test the recombinant proteins for transferrin binding capacity and specificity, 96-well microplates were coated with streptavidin (1 μg / ml in CBS, 100 μl / well) and incubated overnight at 4° C. After washing 3 times with PBST, the plates were blocked with 1% BSA in PBST for 1 hour at room temperature. After washing 3 times with PBST, biotinylated human or mouse transferrin protein (1 ug / ml in PBS, 100 ul / well) was added and incubated for 1 hour at room temperature. After washing 3 times with PBST, purified VHH-OVA-His protein was added and incubated for 1 hour at room temperature (serial dilutions starting at 10 ug / ml in PBS, either pH 7.4 or pH 6.0, 100 ul / well). After sequential incubation with rabbit anti-chicken egg albumin (OVA) and secondary anti-rabbit IgG-HRP, the plates were washed 3 times with PBST and incubated with substrate solution and stop solution as described above for phage ELISA. To illustrate the binding activity of recombinant VHH-OVA-His to native human transferrin (Sigma), representative data are shown in FIG. 2A (pH 7.4, holotransferrin) or FIG. 2B (pH 6.0, apotransferrin).
[0248] 2.6 VHH binding did not disrupt transferrin / TfR1 interaction in HEK293F-hTFR1 cells HEK293F-hTfR1 cells were prepared by transfecting a GFP-tagged hTfR1 expression plasmid into HEK293F cells. A stable pool was used for this assay. Briefly, engineered HEK293F cells expressing hTfR1 were cultured with OPM-293 CD05 medium in a cell shaker at 37°C, 8% CO2 and saturated humidity. HEK293F-hTfR1 cells were harvested, counted, blocked with blocking buffer for 30 min at 37°C, and then 1 × 10 per reaction was added. 6Cells were used and mixed with VHH-OVA-His or control protein solution (final concentration 10 μg / mL) with or without transferrin (final 5 μg / mL) and with or without iron citrate solution (final 0.2 mg / mL) at pH 7.4 or pH 6.0. Cells were washed twice by centrifugation at 300 g for 5 min at 4° C. before rabbit anti-OVA antibody and secondary anti-rabbit IgG-AF647 (all prepared in blocking buffer). Cells were scanned on a CytoFLEX (Beckman). The data was analyzed using CytoExpert 2.4 software to determine 1) differential binding of VHH-OVA-His proteins to cells (transferrin binding does not interfere with transferrin / TfR1 interaction on the cell surface); 2) dependency on transferrin (specificity for transferrin); 3) dependency on TfR1 (specificity for TfR1-mediated cell binding); 4) dependency on pH value and Fe3+ (specificity for iron-associated holotransferrin or iron-free apotransferrin). The data (below and in Figure 3) showed that selected transferrin-binding VHHs such as SLN0042, SLN0043, SLN0044, SLN0049, SLN0062, SLN0064, SLN0065, SLN0056, SLN0071 and SLN0072 do not interfere with transferrin / TfR1 interaction and can associate with TfR1 on the cell surface only through binding to transferrin. The data also confirmed the results from the ELISA which showed that some selected VHHs have different affinities for holo-transferrin and apo-transferrin. [Table 1]
[0249] 2.7 Epitope binning Epitope binning was used to distinguish different "bins" with different proteins, since antibodies in different "bins" bind different epitopes and exhibit different functional characteristics.
[0250] To perform epitope binning, 96-well microplates were coated with 5 μg / mL of each VHH-OVA-His recombinant protein (100 μL / well in CBS buffer) and incubated overnight at 4°C. After washing and blocking as described above for ELISA, a crossww check board reaction was performed by adding a mixture of biotinylated human transferrin (1 μg / mL final) and VHH-OVA-His protein (5 μg / mL final) and incubated for 1 h at room temperature. Biotinylated transferrin bound to the VHH-OVA-His used for coating was detected with streptavidin-HRP and a corresponding method. The data shown in Figure 4 showed that the selected VHHs belonged to multiple bins that were different, especially from the reference antibodies (VHH1, VHH2, VHH3).
[0251] 2.8 Transcytosis of VHH-OVA-His proteins across Caco-2 cell monolayers Caco-2 cells were plated in a 96-well transwell plate at 2 × 10 cells per well. 4The cells were seeded at 100 μg / mL and cultured for 12 days to form a cell monolayer in the inner chamber (medium was changed every other day in the first week and every day in the second week). On day 13, the monolayer cells were washed with pre-warmed PBS and then incubated in MEM medium containing 0.1% BSA without FBS at 37° C. for 30 min to remove endogenous Tf. Recombinant VHH-OVA-His protein (10 μg / mL) with or without native human transferrin (5 μg / mL), both prepared in MEM medium (pH 7.4) containing 0.1% BSA, was added to the inner chamber (above the monolayer of Caco-2 cells) and incubated at 37° C. for 2 or 24 h. Media was collected from the outer chamber at the indicated time points for quantitative measurement by ELISA by reference to a standard curve generated by using the corresponding VHH-OVA-His protein as a control. The integrity of the Caco-2 cell monolayer was tested by Lucifer Yellow (LY) rejection assay according to the manufacturer's instructions. Wells with Lucifer Yellow signal from the outer chamber compared to the inner chamber signal exceeding 0.1% (basal level of passive translocation) will be considered as an incomplete cell monolayer for measurement and therefore discarded.
[0252] Quantitative ELISA measurements were performed as described above by using specific antibodies. Briefly, microplates were coated with rabbit anti-OVA polyclonal antibody (5 μg / mL in CBS buffer), and test articles or controls for standard curve (VHH-OVA-His protein) were added and detected with biotinylated anti-OVA antibody and subsequent streptavidin-HRP conjugate. A standard curve was generated by using recombinant VHH-OVA-His protein serially diluted from 1000 ng / mL to 0 with a dilution factor of 3. The assay was qualified with an inter-assay CV of less than 20% and a recovery rate of more than 90%.
[0253] The data shown in Figure 7 suggested that VHHs have variable abilities to cross Caco-2 cell monolayers, reflecting in part their affinity for human transferrin or epitopes on transferrin for binding. The results also suggested an important role for transferrin in VHH-enabled transmembrane absorption of biological molecules through the intestinal epithelium (Figure 7B).
[0254] Humanization of selected VHHs VHHs with expected properties in enabling transmembrane translocation of fusion OVA protein, as well as VHHs with fewer development risk factors, were selected for humanization. CDR residues within the selected VHHs were determined and annotated with the Kabat numbering system. N-glycosylation and deamination sites within the CDRs, N-glycosylation sites within or close to the CDRs, or cysteines are considered risk factors for future development. VHH humanization was performed according to standard procedures of CDR grading and structure refinement. Upon humanization design, recombinant DNA constructs were made to produce recombinant VHH-OVA-His, as described above for the ELISA-based and FACS-based binding assays. Humanized sequences with affinity equal to or greater than that of the original VHH for transferrin, while having acceptable levels of expression and stability, were selected for further development.
[0255] FIG. 5 showed that the humanized VHH variants had a similar profile as the original VHH with respect to their binding to transferrin.
[0256] Example 3. Use of Tf-binding VHHs to extend the half-life of their associated entities Fusion proteins were produced using recombinant DNA technology by fusing the indicated proteins at the C-terminus or N-terminus of VHH with or without a linker. Proteins were purified to homogeneity, formulated in appropriate buffers, and quantified by Bradford assay for use in in vivo studies. All animal procedures were reviewed and approved by the Institutional Review Board (IRB).
[0257] Mice of different genetic strains, including C57BL / 6, Balb / c and CR6, were grouped based on genetic background, sex and weight. Test articles, such as proteins fused to transferrin binding proteins, as well as negative controls (recombinant proteins produced in the same way but containing VHHs that do not bind to transferrin), were administered by IV or SC injection at a dose of 3 mg / kg with or without co-administration of human transferrin (5 mg / kg). For the group co-administered with transferrin, daily administration of 5 mg / kg human transferrin was continued for 10 days.
[0258] To determine the serum half-life of the test article in mice, 40 μL of whole blood was collected from the subcutaneous vein at the corner of the eye at multiple time points. After the collected whole blood was left at room temperature for 1 hour, serum was collected by centrifugation at 10000 rpm for 10 minutes, and the concentration of VHH fusion protein in serum was measured by quantitative ELISA. For OVA-VHH-His protein or GLP-1-VHH-His protein, respectively, rabbit anti-OVA polyclonal antibody (Sigma C6534-2mL) or monoclonal anti-GLP-1 antibody was paired with biotinylated rabbit anti-VHH antibody (GeneScript, A02015-200) for specific and quantitative measurement by reference to a standard curve made with purified recombinant protein by using a qualified protocol with inter-assay CV less than 20% and recovery rate more than 90%. PK parameters were calculated by PKsovler software.
[0259] The results shown in Figure 6 demonstrated that transferrin-binding VHHs were able to extend the serum half-life of their associated OVA as well as GLP-1, and that such an effect depended on the affinity of the VHH for transferrin and the epitope used for binding.
[0260] Example 4 Transferrin-binding VHHs enabled oral delivery of associated entities As in the half-life test, the grouped mice were anesthetized using 250 mg / kg tribromoethanol, and then the abdominal hair of the mice was shaved and disinfected with iodine tincture and alcohol. The skin of the mid-abdomen was cut into approximately 0.5-1 cm lengths with surgical scissors, and transferrin and Fe were removed. 3+ The duodenum was exposed for injection of the test article or control (purified VHH-OVA-His protein) with or without a mixture of. The wound was disinfected with iodine tincture and sutured. Alternatively, the test article or control was administered by intragastric injection by inserting a gavage needle into the stomach of the mouse. After oral administration, blood samples were taken at multiple time points and serum was collected as described above. The concentration of VHH fusion protein was quantified according to the procedure described in Example 3.
[0261] The data presented in Figure 7 showed that transferrin-binding VHHs enabled orally administered VHH-OVA fusion proteins to cross the intestinal epithelium and be absorbed into the bloodstream, thus demonstrating the feasibility of delivering therapeutic biologics through the oral route of administration.
[0262] Example 5 Transferrin-binding VHHs enabled associated entities to cross the blood-brain barrier As in the half-life study, mice were administered purified recombinant protein (e.g., VHH-OVA-His) at 10 mg / kg by IV injection, with or without human transferrin at 10 mg / kg by IP injection. At multiple time points after administration, brains were harvested and frozen in liquid nitrogen after perfusion with 20 mL of PBS. Proteins were extracted according to standard procedures for quantitative ELISA-based measurements. One quantitative ELISA format used rabbit anti-OVA polyclonal antibody (Sigma C6534-2mL) for coating and biotinylated rabbit anti-VHH antibody (GeneScript, A02015-200) for detection. The data shown in Figure 8 showed that the test articles (VHHs that demonstrated binding ability to transferrin) significantly increased the levels of the test articles in brain tissue (about 1.03% to about 3.5% 24 hours after administration of the selected VHHs in terms of the mean %ID or percentage of the injected dose) compared to the negative control (SLN0066, one VHH that does not bind to transferrin, SEQ ID NO: 110). The data also clearly showed that VHH-enabled BBB crossing was associated with transferrin (the group co-administered with transferrin had about 3.2-fold higher %ID than the group treated with VHH-OVA-His alone).
[0263] By using humanized VHH variants that share the same CDRs (and therefore are believed to bind the same epitope on transferrin) but with different affinities, the effect of the affinity of the VHH for transferrin on their ability to mediate BBB crossing was also determined. The data in Figure 8C further supported the conclusion on the transferrin binding dependency of VHH-enabled BBB crossing ability, but also clearly suggested a relationship between the affinity of the VHH for transferrin and its ability to mediate BBB crossing. Higher BBB crossing was observed with VHH variants with higher affinity for transferrin.
[0264] Example 6 Transferrin-binding VHHs enabled intracellular delivery of their associated entities The levels of transferrin receptor are also elevated on the membrane surface of multiple types of cells, e.g., tumor cells. Thus, transferrin-binding VHHs would be advantageous for targeted drug delivery, especially intracellular delivery to tumor cells. To test such a hypothesis, recombinant VHH-PE38-His protein was produced in Escherichia coli (E. coli) and purified to homogeneity. The efficacy of intracellular delivery was tested in monolayer cultures of Hepa-G2 cells (constitutively expressing TfR) and MDCK cells (with or without ectopic TfR1 expression from transfected recombinant plasmids). Briefly, cells were seeded at the desired density in 100 μL of culture medium in 96-well microplates and cultured overnight at 37°C. After washing the cells with fresh pre-warmed medium, serially diluted VHH-PE38-His with or without human transferrin prepared in culture medium was added to the cell cultures. At multiple time points after treatment, viable cells were quantified using CellTiter-Glo® reagent as instructed by the manufacturer's manual. Luminescence signals were recorded with integration times of 0.25 to 1 s per well, and data were analyzed in GraphPad.
[0265] The data shown in Figure 9 demonstrated that transferrin-binding VHHs enable intracellular delivery of associated entities to cells expressing the transferrin receptor on their surface, and such ability is dependent on the transferrin-binding activity of the VHHs. VHHs with different epitope utilization (belonging to different bins or having different CDR sequences) also demonstrated different efficacy in intracellular delivery.
[0266] Example 7 Transferrin-binding VHHs enable organ- or tissue-targeted delivery of associated entities The biodistribution of intravenously administered recombinant proteins (e.g., VHH-OVA-His) was also investigated in mice with different genetic backgrounds. At multiple time points after intravenous injection, samples were collected from liver, lung, bone marrow, heart, muscle and blood etc. after perfusion of blood vessels with 30 mL of PBS. Samples were weighed and homogenized to extract soluble proteins for quantitative ELISA-based measurements as described above. Data were normalized to tissue weight or volume with reference to a standard curve generated with purified recombinant protein. Biodistribution of VHH-OVA-His protein was analyzed by fold change compared to a control VHH that does not bind transferrin. Data shown in Figure 10 showed that selected transferrin-binding VHHs enable targeted delivery to liver, brain, bone marrow, lung, muscle, kidney, eye and other organs or tissues expressing transferrin receptor. The transferrin-binding VHHs in the present invention may have potential applications in targeted drug delivery to various tissues, especially brain, liver and bone marrow.
[0267] Although preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. The present invention is not intended to be limited by the specific examples provided herein. Although the present invention has been described with reference to the above specification, the description and illustration of the embodiments herein are not meant to be construed in a limiting sense. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the present invention. Furthermore, it should be understood that all aspects of the present invention are not limited to the specific depictions, configurations, or relative proportions shown herein which depend upon a variety of conditions and variables. It should be understood that various alternatives to the embodiments of the present invention described herein may be used in the practice of the present invention. It is therefore contemplated that the present invention encompasses any such alternatives, modifications, variations, or equivalents. It is intended that the following claims define the scope of the present invention, and that methods and structures within the scope of these claims and their equivalents are covered thereby.
Claims
1. One method of translocating molecules across cell membranes is by using transferrin binding proteins.
2. The method of claim 1 , wherein the transferrin binding protein comprises a transferrin binding antibody or a fragment thereof.
3. 3. The method of claim 1 or 2, used for drug delivery across the cell membrane of polarized and / or non-polarized cells.
4. The method of claim 3 , wherein the polarized and / or non-polarized cells express a transferrin receptor on their cell membrane.
5. 5. The method of claim 1, wherein the drug delivery across the cell membrane of a polarized cell comprises intracellular delivery of the drug and / or recycling of endocytosed drug into the circulation.
6. 6. The method of any one of claims 1 to 5, wherein the drug delivery across a cell membrane of a non-polarized cell comprises crossing the blood-brain barrier (BBB) for a systemically administered drug targeted to the central nervous system (CNS), crossing the intestinal epithelium for an orally administered drug, and / or permeation of a drug through multiple layers of cells in a solid tissue.
7. 7. The method of claim 1, wherein the drug comprises a therapeutic or diagnostic agent.
8. The method of any one of claims 1 to 7, wherein the drug comprises a small molecule compound, a synthetic peptide, a recombinant protein, an antibody or antibody fragment, an enzyme, a portion of a nucleotide acid sequence, a liposome, a lipid nanoparticle, a drug vehicle, a modified virus and / or a gene therapy vector.
9. 9. The method of claim 1, wherein the drug is associated with the transferrin binding protein through chemical conjugation or genetic fusion.
10. A transferrin binding protein capable of extending the circulatory half-life of its associated entity.
11. 11. The transferrin binding protein of claim 10, which enables a fusion protein comprising the transferrin binding protein to cross the blood-brain barrier (BBB).
12. 12. The transferrin binding protein of claim 10 or 11, for use in oral delivery of a drug.
13. 13. A transferrin binding protein according to any one of claims 10 to 12, which enables intracellular delivery of its associated entity to a transferrin receptor expressing cell.
14. 14. The transferrin binding protein of claim 10, which is capable of specifically binding to transferrin and does not interfere with the interaction between transferrin and transferrin receptor 1.
15. 15. The transferrin binding protein of any one of claims 10 to 14, wherein the transferrin is human transferrin.
16. 16. The transferrin binding protein of claim 10, having a higher affinity for iron-containing holotransferrin than for iron-free apotransferrin.
17. 17. The transferrin binding protein of any one of claims 10 to 16, comprising a monoclonal antibody, a single chain antibody fragment, a single domain antibody fragment, an engineered protein, or a peptide.
18. 18. The transferrin binding protein of any one of claims 10 to 17, wherein the antibody or antibody fragment comprises an animal-derived sequence, a humanized sequence, a fully human sequence, a chimeric sequence, or a synthetic sequence.
19. 19. A transferrin binding protein according to any one of claims 10 to 18, wherein the antibody or antibody fragment is a single domain antibody fragment VHH.
20. 20. The transferrin binding protein of any one of claims 10 to 19, comprising a CDR3, wherein the CDR3 comprises an amino acid sequence set forth in any one of SEQ ID NOs: 45 to 69.
21. 21. The transferrin binding protein of any one of claims 10 to 20, comprising a CDR2, wherein the CDR2 comprises an amino acid sequence set forth in any one of SEQ ID NOs: 22 to 44.
22. 22. A transferrin binding protein according to any one of claims 10 to 21, comprising a CDR1, wherein the CDR1 comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1 to 21.
23. 23. The transferrin binding protein according to any one of claims 10 to 22, comprising a heavy chain variable region VH, and wherein the heavy chain variable region VH comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 70 to 104.
24. 24. A polypeptide comprising a transferrin binding protein according to any one of claims 10 to 23 and a therapeutic entity.
25. 25. The polypeptide of claim 24, wherein the therapeutic entity is an engineered cytotoxic Pseudomonas exotoxin A (PE38).
26. 25. The polypeptide of claim 24, wherein the therapeutic entity is glucagon-like peptide-1 (GLP-1) or a variant thereof.
27. 27. The polypeptide of any one of claims 24 to 26, wherein the therapeutic entity and the antigen binding protein are directly or indirectly linked.
28. 27. The polypeptide of any one of claims 24 to 26, wherein the therapeutic entity and the transferrin binding protein are linked through a linker.
29. 30. One or more isolated nucleic acid molecules encoding a transferrin binding protein according to any one of claims 10 to 23 or a polypeptide according to any one of claims 24 to 29.
30. 30. A vector comprising the nucleic acid molecule of claim 29.
31. 33. A cell comprising the nucleic acid molecule of claim 32 or the vector of claim 30.
32. 32. A method for preparing a transferrin binding protein according to any one of claims 10 to 23 or a polypeptide according to any one of claims 24 to 26, comprising culturing a cell according to claim 31 under conditions which allow the transferrin binding protein or the polypeptide to be expressed.
33. A pharmaceutical composition comprising a transferrin binding protein according to any one of claims 10 to 23 and a polypeptide according to any one of claims 24 to 26.
34. 24. A method for increasing the circulation half-life of a therapeutic entity, wherein the therapeutic entity is directly or indirectly linked to a transferrin binding protein according to any one of claims 10 to 23.
35. 24. A method for delivering a therapeutic or diagnostic agent to a cell or organ expressing a transferrin receptor, comprising using a transferrin binding entity according to any one of claims 10 to 23.
36. 24. A method for targeted drug delivery across the blood-brain barrier, intestinal epithelium and / or cell membranes expressing transferrin receptors, comprising using a transferrin binding entity according to any one of claims 10 to 23.
37. 24. A method for oral delivery of a therapeutic or diagnostic entity, wherein the therapeutic or diagnostic entity is directly or indirectly linked to an antigen binding protein according to any one of claims 10 to 23.
38. 24. A method for intracellular delivery of a therapeutic entity, wherein the therapeutic entity is directly or indirectly linked to an antigen binding protein according to any one of claims 10 to 23.
Citation Information
Patent Citations
Transferrin receptor-binding molecules, conjugates thereof and their uses
CN113474369A
Enhancement of transport of therapeutic molecules across the blood brain barrier
US20150210762A1
Compositions and methods for increasing protein half-life in a serum
US20160200830A1
